Jeffrey R. Binder, CEO of Biomet, attributed the lower-than-expected increase to a deceleration of procedural growth in the market. However, he remains optimistic about long-term growth.
The company reported a 3 percent and 7 percent increase in orthopedic reconstructive sales in the world and U.S., respectively. Knee sales increased by 4 percent, extremity sales increased by 25 percent, and sports medicine sales grew by 15 percent worldwide.
Read the release on Biomet’s 1Q FY report.
Read other coverage on Biomet:
– Biomet Announces 4Q FY 2010 Financial Results
– Biomet Acquires Massachusetts’ Cytosol Laboratories
– Biomet Sports Medicine Mobile Learning Center to Provide Product Demonstration and Education
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
